Search

The article cites a study that describes the basic characteristics of psoriatic disease, a dermatologic disorder that affects residents in the U.S. It discusses the need for appropriate management for early and aggressive intervention of this condition. It highlights the principles that maximizes treatment outcomes by giving tumor necrosis factor-alpha antagonist therapy.

The article presents patient specialized education for the awareness of psoriatic disease. Health education for the disease has been conducted by the Phototherapy Education and Research Center to improve the knowledge and management of the disease. It was known that psoriasis is a chronic inflammatory skin disease which is linked to arthritides and can be managed through medical and non medical methods.

The article presents a study on the effective management and treatment of psoriatic itch. Patients with chronic pruritus often have difficulty sleeping, problems concentrating, lowered sex drive, and depression. The treatments recommended for psoriatic itch are tar products, topical corticosteroids, topical salicylates, agents that alter skin sensation, phototherapy, vitamin D analogs, topical immunomodulators, methotrexate, oral mirtazapine, and biologics.

Presents information on calcipotriene, a synthetic analog of vitamin D3 which is a safe and effective option in the treatment of plaque psoriasis. Explanation that vitamin D plays a critical role in maintaining adequate levels of serum calcium and phosphorous that are both essential for adequate mineralization of bone; Vitamin D synthesis; Discussion on the treatment of psoriasis.

The article reports that an oral systemic drug Soriatane (acitretin) manufactured by Connectics Corp. had a long-term efficacy on moderate-to-severe plaque-type psoriasis if taken at lower dosage. The Phase IV clinical study involving 77 adults with psoriasis reveals that taking 25 milligram of Soriatane had reduced the Psoriasis area and Severity Index by 50 up to 75 percent.